<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">BEXAROTENE</span><br/>(bex-a-ro'teen)<br/><span class="topboxtradename">Targretin<br/></span><b>Classifications:</b> <span class="classification">antineoplastic agent</span>; <span class="classification">skin and mucous membrane agent</span>; <span class="classification">retinoid</span><br/><b>Prototype: </b>Isotretinoin<br/><b>Pregnancy Category: </b>X<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>75 mg capsules; 1% gel</p>
<h1><a name="action">Actions</a></h1>
<p>Selectively binds to retinoid X receptors (RXR). Activation of the RXR pathway leads to cell death by interfering with cellular
         differentiation and proliferation of cells.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Inhibits the growth of tumor cells of squamous (skin) cell origin inducing tumor regression.</p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of cutaneous manifestations of cutaneous T-cell lymphoma.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to bexarotene; pregnancy (X), lactation. Safety and efficacy in children are not established.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Coronary artery disease; diabetes mellitus; alcoholism, history of pancreatitis, hepatitis; elevated triglycerides, hepatic
         impairment.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">T-Cell Lymphoma</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 300 mg/m<sup>2</sup>/d as a single dose with a meal, if no response after 8 wk, may increase to 400 mg/m<sup>2</sup>/d. Adjust dose downward in 100 mg/m<sup>2</sup>/d increments if toxicity occurs <span class="rdroute">Topical</span> Apply once q.o.d. times 1 week, increase frequency at weekly intervals to once per day, b.i.d., t.i.d., and q.i.d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give drug with or immediately following a meal.</li>
<li>Do not give oral drug with grapefruit or grapefruit juice.</li>
<li>Do not initiate therapy in a woman of childbearing age until the possibility of pregnancy has been completely ruled out.</li>
</ul><span class="adminroutetype">Topical</span><br/><ul>
<li>Apply a generous coating only to skin lesions; avoid normal skin.</li>
<li>Do not cover with clothing until gel dries.</li>
<li>Do not apply more frequently than prescribed.</li>
<li>Store capsules and gel at 20°25° C (36°77° F). Protect from light and avoid high temperatures
            and humidity after bottle or tube is opened.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span>
<span class="speceff-common">Headache, asthenia, infection,</span> chills, fever, flu-like syndrome, back pain, bacterial infection. <span class="typehead">CNS:</span> Insomnia. <span class="typehead">CV:</span>
<span class="speceff-common">Peripheral edema.</span>
<span class="typehead">GI:</span>
<span class="speceff-common">Abdominal pain, nausea,</span> diarrhea, vomiting, anorexia. <span class="typehead">Endocrine:</span>
<span class="speceff-common">Hyperthyroidism.</span>
<span class="typehead">Hematologic:</span>
<span class="speceff-common">Leukopenia,</span> anemia, hypochromic anemia. <span class="typehead">Metabolic:</span>
<span class="speceff-common">Hyperlipidemia, hypercholesterolemia,</span> increased LDH. <span class="typehead">Skin:</span>
<span class="speceff-common">Rash, dry skin,</span> exfoliative dermatitis, alopecia, photosensitivity. 
      <h1><a name="interactions">Interactions</a></h1> No clinically significant interactions established. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Best absorption with a fat-containing meal. <span class="typehead">Peak:</span> 2 h. <span class="typehead">Distribution:</span> &gt;99% protein bound. <span class="typehead">Metabolism:</span> Metabolized to 4 metabolites by CYP 3A4. <span class="typehead">Elimination:</span> Eliminated primarily in bile. <span class="typehead">Half-Life:</span> 7 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor (with oral dose) for S&amp;S of: hypothyroidism, hypertriglyceridemia, hypercholesterolemia, and pancreatitis.</li>
<li>Lab tests (with oral dose): Baseline blood lipids, then weekly for 24 wks, and every 8 wks thereafter; baseline liver
            function tests, then repeat at 1, 2, 4 wks, and every 8 wks thereafter; baseline WBC and thyroid function tests, then repeat
            periodically thereafter; periodic serum calcium; for females, pregnancy test q mo throughout therapy.
         </li>
<li>Withhold oral drug and notify physician if triglycerides &gt;400 mg/dL or AST, ALT, or bilirubin &gt;3 times upper limit of normal.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Use effective methods of contraception (both men and women) while taking/using this drug and for at least 1 mo after the last
            dose of the drug.
         </li>
<li>Do not take this drug if you are or could be pregnant.</li>
<li>Do not take this drug (oral form) if you are also taking gemfibrozil.</li>
<li>Report immediately any of the following: Swelling in the face, lips, or wheezing; persistent bloating, constipation, diarrhea,
            vomiting, or stomach pain; persistent headache, severe drowsiness or weakness.
         </li>
<li>Limit vitamin A intake to <img src="../images/special/lesserorequal.gif"/>15,000 IU/d while taking this drug (oral form).</li>
<li>Report changes in vision to the physician. An ophthalmologic evaluation may be needed.</li>
<li>Limit exposure to sunlight or sun lamps and wear sunscreen.</li>
<li>Do not use insect repellents that contain the chemical, DEET, while using bexarotene gel.</li>
<li>Report significant skin irritation.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>